India Contract Development and Manufacturing (CDMO) Market - 2025-2033
India Contract Development and Manufacturing (CDMO) Market Size
The India contract development and manufacturing (CDMO) market size reached US$ 16.27 Billion in 2024 and is expected to reach US$ 31.23 Billion by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033.
India Contract Development and Manufacturing (CDMO) Market Overview
The contract development and manufacturing organization (CDMO) market in India is experiencing rapid growth, driven by the country’s expanding pharmaceutical industry, increasing outsourcing trends in drug development and manufacturing, and an enhanced regulatory environment. India is increasingly being seen as a key player in the CDMO market, largely due to its established expertise in generic drug production, competitive pricing, skilled workforce, and cost-effective services for pharmaceutical companies worldwide.
The market is poised for significant expansion in the coming years, supported by strong demand for both small molecule and biologic drugs, advancements in contract manufacturing services, and a strong push towards more efficient, scalable production capacities. Indian CDMOs are becoming critical partners for both domestic and international pharmaceutical companies looking to accelerate time-to-market while reducing manufacturing costs and regulatory complexity.
India Contract Development and Manufacturing (CDMO) Market Dynamics: Drivers & Restraints
High-quality generic drug production is significantly driving the India Contract Development and Manufacturing (CDMO) market growth
The rising global demand for affordable healthcare solutions, especially in developed markets like the U.S. and Europe, is pushing pharmaceutical companies to look for cost-effective manufacturing alternatives. As patents on blockbuster drugs expire, demand for generic versions which offer the same therapeutic benefits but at a much lower cost skyrockets. India, being the world’s largest producer of generic drugs, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand, is well-positioned to meet this demand through its robust CDMO infrastructure.
For instance, Cipla, one of India’s leading pharmaceutical companies, Cipla has produced 200+ generics and complex APIs and has been able to successfully manufacture many generic versions of major drugs, such as AIDS medications, respiratory, and cancer treatments, at a fraction of the cost of branded alternatives. This has made Cipla a key player in generic drug supply and a preferred partner for international pharmaceutical companies.
As patents for many blockbuster drugs expire, there is a substantial opportunity for Indian CDMOs to step in and produce generic versions. This trend, especially in therapeutic areas like oncology, cardiology, and diabetes, has created a massive demand for generics worldwide. Indian CDMOs, with their established production capabilities, can rapidly scale up manufacturing to supply global markets, increasing their market share.
For instance, the generic version of Glivec (imatinib), a cancer drug by Novartis, is one of the most notable examples where Indian CDMOs, such as Natco Pharma, capitalized on the expiration of patents and offered affordable alternatives to millions of cancer patients across the globe. This growth is driven by the expiration of patents on branded drugs, which opens up significant opportunities for generics production and exports, reinforcing India’s leadership in the global pharmaceutical industry.
Regulatory compliance and complexities are hampering the market growth
Regulatory compliance and complexities are significant challenges that can hamper the growth of the India contract development and manufacturing organization (CDMO) market. While India has made substantial strides in aligning with global regulatory standards, the complexity of regulations, combined with stringent requirements for international certifications, creates several obstacles for CDMOs in the country.
Indian CDMOs aiming to serve global markets must comply with regulations set by international authorities like the U.S. FDA, European Medicines Agency (EMA), and World Health Organization (WHO). The process to secure approval from these agencies can be time-consuming and complex, requiring multiple rounds of inspections, documentation, and adherence to strict Good Manufacturing Practices (GMP). This delay in approval can result in missed market opportunities, especially in highly competitive sectors like generics, biologics, and biosimilars, where time-to-market is critical. Failure to obtain timely approvals can lead to lost contracts, production halts, and financial losses.
India Contract Development and Manufacturing (CDMO) Market, Segment Analysis
The India contract development and manufacturing (CDMO) market is segmented based on service type, scale of operation, and end-user.
The contract manufacturing services from service type segment holds 53.78% in the India contract development and manufacturing (CDMO) market
India's cost-effectiveness is a major reason why contract manufacturing services are highly in demand. Indian CDMOs offer high-quality manufacturing at lower costs, driven by lower labor and operational expenses compared to Western markets. This makes India a preferred destination for pharmaceutical companies looking to outsource their manufacturing needs while maintaining a focus on cost reduction.
For instance, Indian companies like Aurobindo Pharma and Lupin are leaders in the contract manufacturing space, providing services to major international pharmaceutical companies. Aurobindo, for instance, produces a variety of generic formulations and active pharmaceutical ingredients (APIs) for global markets, at significantly lower costs.
India is renowned as the world leader in generic drug manufacturing, and the contract manufacturing services segment heavily capitalizes on this expertise. Indian CDMOs have the capabilities to manufacture high-quality generic drugs, which are in high demand in both developed and developing markets. As patents for branded drugs expire, Indian CDMOs offer a reliable and cost-effective solution for the production of generic medicines.
For instance, Dr. Reddy’s Laboratories, one of India's largest pharmaceutical companies, excels in providing contract manufacturing services for generics. It has partnerships with leading global pharmaceutical companies to manufacture generic formulations and biologics in large quantities, helping these companies lower their production costs while maintaining high-quality standards.
India Contract Development and Manufacturing (CDMO) Market Competitive Landscape
Top companies in the India contract development and manufacturing (CDMO) market include Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Cipla, NATCO Pharma Limited, Hetero Labs Limited, Cadila Pharmaceuticals, Biocon, Intas Pharmaceuticals Ltd., and others.
The India contract development and manufacturing (CDMO) market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures, and 138 pages of expert insights, providing a complete view of the market landscape.
The India contract development and manufacturing (CDMO) market size reached US$ 16.27 Billion in 2024 and is expected to reach US$ 31.23 Billion by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033.
India Contract Development and Manufacturing (CDMO) Market Overview
The contract development and manufacturing organization (CDMO) market in India is experiencing rapid growth, driven by the country’s expanding pharmaceutical industry, increasing outsourcing trends in drug development and manufacturing, and an enhanced regulatory environment. India is increasingly being seen as a key player in the CDMO market, largely due to its established expertise in generic drug production, competitive pricing, skilled workforce, and cost-effective services for pharmaceutical companies worldwide.
The market is poised for significant expansion in the coming years, supported by strong demand for both small molecule and biologic drugs, advancements in contract manufacturing services, and a strong push towards more efficient, scalable production capacities. Indian CDMOs are becoming critical partners for both domestic and international pharmaceutical companies looking to accelerate time-to-market while reducing manufacturing costs and regulatory complexity.
India Contract Development and Manufacturing (CDMO) Market Dynamics: Drivers & Restraints
High-quality generic drug production is significantly driving the India Contract Development and Manufacturing (CDMO) market growth
The rising global demand for affordable healthcare solutions, especially in developed markets like the U.S. and Europe, is pushing pharmaceutical companies to look for cost-effective manufacturing alternatives. As patents on blockbuster drugs expire, demand for generic versions which offer the same therapeutic benefits but at a much lower cost skyrockets. India, being the world’s largest producer of generic drugs, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand, is well-positioned to meet this demand through its robust CDMO infrastructure.
For instance, Cipla, one of India’s leading pharmaceutical companies, Cipla has produced 200+ generics and complex APIs and has been able to successfully manufacture many generic versions of major drugs, such as AIDS medications, respiratory, and cancer treatments, at a fraction of the cost of branded alternatives. This has made Cipla a key player in generic drug supply and a preferred partner for international pharmaceutical companies.
As patents for many blockbuster drugs expire, there is a substantial opportunity for Indian CDMOs to step in and produce generic versions. This trend, especially in therapeutic areas like oncology, cardiology, and diabetes, has created a massive demand for generics worldwide. Indian CDMOs, with their established production capabilities, can rapidly scale up manufacturing to supply global markets, increasing their market share.
For instance, the generic version of Glivec (imatinib), a cancer drug by Novartis, is one of the most notable examples where Indian CDMOs, such as Natco Pharma, capitalized on the expiration of patents and offered affordable alternatives to millions of cancer patients across the globe. This growth is driven by the expiration of patents on branded drugs, which opens up significant opportunities for generics production and exports, reinforcing India’s leadership in the global pharmaceutical industry.
Regulatory compliance and complexities are hampering the market growth
Regulatory compliance and complexities are significant challenges that can hamper the growth of the India contract development and manufacturing organization (CDMO) market. While India has made substantial strides in aligning with global regulatory standards, the complexity of regulations, combined with stringent requirements for international certifications, creates several obstacles for CDMOs in the country.
Indian CDMOs aiming to serve global markets must comply with regulations set by international authorities like the U.S. FDA, European Medicines Agency (EMA), and World Health Organization (WHO). The process to secure approval from these agencies can be time-consuming and complex, requiring multiple rounds of inspections, documentation, and adherence to strict Good Manufacturing Practices (GMP). This delay in approval can result in missed market opportunities, especially in highly competitive sectors like generics, biologics, and biosimilars, where time-to-market is critical. Failure to obtain timely approvals can lead to lost contracts, production halts, and financial losses.
India Contract Development and Manufacturing (CDMO) Market, Segment Analysis
The India contract development and manufacturing (CDMO) market is segmented based on service type, scale of operation, and end-user.
The contract manufacturing services from service type segment holds 53.78% in the India contract development and manufacturing (CDMO) market
India's cost-effectiveness is a major reason why contract manufacturing services are highly in demand. Indian CDMOs offer high-quality manufacturing at lower costs, driven by lower labor and operational expenses compared to Western markets. This makes India a preferred destination for pharmaceutical companies looking to outsource their manufacturing needs while maintaining a focus on cost reduction.
For instance, Indian companies like Aurobindo Pharma and Lupin are leaders in the contract manufacturing space, providing services to major international pharmaceutical companies. Aurobindo, for instance, produces a variety of generic formulations and active pharmaceutical ingredients (APIs) for global markets, at significantly lower costs.
India is renowned as the world leader in generic drug manufacturing, and the contract manufacturing services segment heavily capitalizes on this expertise. Indian CDMOs have the capabilities to manufacture high-quality generic drugs, which are in high demand in both developed and developing markets. As patents for branded drugs expire, Indian CDMOs offer a reliable and cost-effective solution for the production of generic medicines.
For instance, Dr. Reddy’s Laboratories, one of India's largest pharmaceutical companies, excels in providing contract manufacturing services for generics. It has partnerships with leading global pharmaceutical companies to manufacture generic formulations and biologics in large quantities, helping these companies lower their production costs while maintaining high-quality standards.
India Contract Development and Manufacturing (CDMO) Market Competitive Landscape
Top companies in the India contract development and manufacturing (CDMO) market include Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Cipla, NATCO Pharma Limited, Hetero Labs Limited, Cadila Pharmaceuticals, Biocon, Intas Pharmaceuticals Ltd., and others.
The India contract development and manufacturing (CDMO) market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures, and 138 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Service Type
2.4. Snippet by Scale of Operation
2.5. Snippet by End-User
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. High-Quality Generic Drug Production
3.1.1.2. Growing Vaccine Manufacturing Capabilities
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Regulatory Compliance and Complexities
3.1.2.2. Dependence on Raw Material Imports
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. High Demand for Complex Drug Formulations
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. India Regulatory and Reimbursement Landscape
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
5. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SERVICE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
5.1.2. Market Attractiveness Index, By Service Type
5.2. Contract Development Services*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Preclinical Development
5.2.4. Formulation Development
5.2.5. Process Development
5.2.6. Clinical Trial Material Production
5.3. Contract Manufacturing Services
5.3.1. API/Bulk Drug Manufacturing
5.3.2. Finished Dosage Form Manufacturing
5.4. Contract Packaging Services
6. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SCALE OF OPERATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Scale of Operation
6.1.2. Market Attractiveness Index, By Scale of Operation
6.2. Preclinical*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Clinical (Phase I, II, III)
6.4. Commercial Manufacturing
7. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Pharmaceutical Companies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Biotechnology Companies
7.4. Academic and Research Institutions
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Aurobindo Pharma Limited*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Dr. Reddy’s Laboratories Ltd.
9.3. Sun Pharmaceutical Industries Ltd.
9.4. Lupin Limited
9.5. Cipla
9.6. NATCO Pharma Limited
9.7. Hetero Labs Limited
9.8. Cadila Pharmaceuticals
9.9. Biocon
9.10. Intas Pharmaceuticals Ltd.
LIST NOT EXHAUSTIVE
10. ASSUMPTION AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Service Type
2.4. Snippet by Scale of Operation
2.5. Snippet by End-User
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. High-Quality Generic Drug Production
3.1.1.2. Growing Vaccine Manufacturing Capabilities
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Regulatory Compliance and Complexities
3.1.2.2. Dependence on Raw Material Imports
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. High Demand for Complex Drug Formulations
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. India Regulatory and Reimbursement Landscape
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
5. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SERVICE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
5.1.2. Market Attractiveness Index, By Service Type
5.2. Contract Development Services*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Preclinical Development
5.2.4. Formulation Development
5.2.5. Process Development
5.2.6. Clinical Trial Material Production
5.3. Contract Manufacturing Services
5.3.1. API/Bulk Drug Manufacturing
5.3.2. Finished Dosage Form Manufacturing
5.4. Contract Packaging Services
6. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SCALE OF OPERATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Scale of Operation
6.1.2. Market Attractiveness Index, By Scale of Operation
6.2. Preclinical*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Clinical (Phase I, II, III)
6.4. Commercial Manufacturing
7. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Pharmaceutical Companies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Biotechnology Companies
7.4. Academic and Research Institutions
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Aurobindo Pharma Limited*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Dr. Reddy’s Laboratories Ltd.
9.3. Sun Pharmaceutical Industries Ltd.
9.4. Lupin Limited
9.5. Cipla
9.6. NATCO Pharma Limited
9.7. Hetero Labs Limited
9.8. Cadila Pharmaceuticals
9.9. Biocon
9.10. Intas Pharmaceuticals Ltd.
LIST NOT EXHAUSTIVE
10. ASSUMPTION AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 India Contract Development and Manufacturing (CDMO) Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 India Contract Development and Manufacturing (CDMO) Market Value, By Scale of Operation, 2025, 2029 & 2033 (US$ Billion)
Table 3 India Contract Development and Manufacturing (CDMO) Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 India Contract Development and Manufacturing (CDMO) Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 India Contract Development and Manufacturing (CDMO) Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 6 India Contract Development and Manufacturing (CDMO) Market Value, By Scale of Operation, 2025, 2029 & 2033 (US$ Billion)
Table 7 India Contract Development and Manufacturing (CDMO) Market Value, By Scale of Operation, 2022-2033 (US$ Billion)
Table 8 India Contract Development and Manufacturing (CDMO) Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 9 India Contract Development and Manufacturing (CDMO) Market Value, By End-User, 2022-2033 (US$ Billion)
Table 10 Aurobindo Pharma Limited: Overview
Table 11 Aurobindo Pharma Limited: Product Portfolio
Table 12 Aurobindo Pharma Limited: Key Developments
Table 13 Dr. Reddy’s Laboratories Ltd.: Overview
Table 14 Dr. Reddy’s Laboratories Ltd.: Product Portfolio
Table 15 Dr. Reddy’s Laboratories Ltd.: Key Developments
Table 16 Sun Pharmaceutical Industries Ltd.: Overview
Table 17 Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 18 Sun Pharmaceutical Industries Ltd.: Key Developments
Table 19 Lupin Limited: Overview
Table 20 Lupin Limited: Product Portfolio
Table 21 Lupin Limited: Key Developments
Table 22 Cipla: Overview
Table 23 Cipla: Product Portfolio
Table 24 Cipla: Key Developments
Table 25 NATCO Pharma Limited: Overview
Table 26 NATCO Pharma Limited: Product Portfolio
Table 27 NATCO Pharma Limited: Key Developments
Table 28 Hetero Labs Limited: Overview
Table 29 Hetero Labs Limited: Product Portfolio
Table 30 Hetero Labs Limited: Key Developments
Table 31 Cadila Pharmaceuticals: Overview
Table 32 Cadila Pharmaceuticals: Product Portfolio
Table 33 Cadila Pharmaceuticals: Key Developments
Table 34 Biocon: Overview
Table 35 Biocon: Product Portfolio
Table 36 Biocon: Key Developments
Table 37 Intas Pharmaceuticals Ltd.: Overview
Table 38 Intas Pharmaceuticals Ltd.: Product Portfolio
Table 39 Intas Pharmaceuticals Ltd.: Key Developments
Table 1 India Contract Development and Manufacturing (CDMO) Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 India Contract Development and Manufacturing (CDMO) Market Value, By Scale of Operation, 2025, 2029 & 2033 (US$ Billion)
Table 3 India Contract Development and Manufacturing (CDMO) Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 India Contract Development and Manufacturing (CDMO) Market Value, By Service Type, 2025, 2029 & 2033 (US$ Billion)
Table 5 India Contract Development and Manufacturing (CDMO) Market Value, By Service Type, 2022-2033 (US$ Billion)
Table 6 India Contract Development and Manufacturing (CDMO) Market Value, By Scale of Operation, 2025, 2029 & 2033 (US$ Billion)
Table 7 India Contract Development and Manufacturing (CDMO) Market Value, By Scale of Operation, 2022-2033 (US$ Billion)
Table 8 India Contract Development and Manufacturing (CDMO) Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 9 India Contract Development and Manufacturing (CDMO) Market Value, By End-User, 2022-2033 (US$ Billion)
Table 10 Aurobindo Pharma Limited: Overview
Table 11 Aurobindo Pharma Limited: Product Portfolio
Table 12 Aurobindo Pharma Limited: Key Developments
Table 13 Dr. Reddy’s Laboratories Ltd.: Overview
Table 14 Dr. Reddy’s Laboratories Ltd.: Product Portfolio
Table 15 Dr. Reddy’s Laboratories Ltd.: Key Developments
Table 16 Sun Pharmaceutical Industries Ltd.: Overview
Table 17 Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 18 Sun Pharmaceutical Industries Ltd.: Key Developments
Table 19 Lupin Limited: Overview
Table 20 Lupin Limited: Product Portfolio
Table 21 Lupin Limited: Key Developments
Table 22 Cipla: Overview
Table 23 Cipla: Product Portfolio
Table 24 Cipla: Key Developments
Table 25 NATCO Pharma Limited: Overview
Table 26 NATCO Pharma Limited: Product Portfolio
Table 27 NATCO Pharma Limited: Key Developments
Table 28 Hetero Labs Limited: Overview
Table 29 Hetero Labs Limited: Product Portfolio
Table 30 Hetero Labs Limited: Key Developments
Table 31 Cadila Pharmaceuticals: Overview
Table 32 Cadila Pharmaceuticals: Product Portfolio
Table 33 Cadila Pharmaceuticals: Key Developments
Table 34 Biocon: Overview
Table 35 Biocon: Product Portfolio
Table 36 Biocon: Key Developments
Table 37 Intas Pharmaceuticals Ltd.: Overview
Table 38 Intas Pharmaceuticals Ltd.: Product Portfolio
Table 39 Intas Pharmaceuticals Ltd.: Key Developments
LIST OF FIGURES
Figure 1 India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 2 India Contract Development and Manufacturing (CDMO) Market Share, By Service Type, 2024 & 2033 (%)
Figure 3 India Contract Development and Manufacturing (CDMO) Market Share, By Scale of Operation, 2024 & 2033 (%)
Figure 4 India Contract Development and Manufacturing (CDMO) Market Share, By End-User, 2024 & 2033 (%)
Figure 5 India Contract Development and Manufacturing (CDMO) Market Y-o-Y Growth, By Service Type, 2023-2033 (%)
Figure 6 Contract Development Services Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 7 Contract Manufacturing Services Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 8 Contract Packaging Services Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 9 India Contract Development and Manufacturing (CDMO) Market Y-o-Y Growth, By Scale of Operation, 2023-2033 (%)
Figure 10 Preclinical Scale of Operation in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 11 Clinical (Phase I, II, III) Scale of Operation in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 12 Commercial Manufacturing Scale of Operation in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 13 India Contract Development and Manufacturing (CDMO) Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 14 Pharmaceutical Companies End-User in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 15 Biotechnology Companies End-User in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 16 Contract Research Organizations End-User in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 17 Aurobindo Pharma Limited: Financials
Figure 18 Dr. Reddy’s Laboratories Ltd.: Financials
Figure 19 Sun Pharmaceutical Industries Ltd.: Financials
Figure 20 Lupin Limited: Financials
Figure 21 Cipla: Financials
Figure 22 NATCO Pharma Limited: Financials
Figure 23 Hetero Labs Limited: Financials
Figure 24 Cadila Pharmaceuticals: Financials
Figure 25 Biocon: Financials
Figure 26 Intas Pharmaceuticals Ltd.: Financials
Figure 1 India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 2 India Contract Development and Manufacturing (CDMO) Market Share, By Service Type, 2024 & 2033 (%)
Figure 3 India Contract Development and Manufacturing (CDMO) Market Share, By Scale of Operation, 2024 & 2033 (%)
Figure 4 India Contract Development and Manufacturing (CDMO) Market Share, By End-User, 2024 & 2033 (%)
Figure 5 India Contract Development and Manufacturing (CDMO) Market Y-o-Y Growth, By Service Type, 2023-2033 (%)
Figure 6 Contract Development Services Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 7 Contract Manufacturing Services Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 8 Contract Packaging Services Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 9 India Contract Development and Manufacturing (CDMO) Market Y-o-Y Growth, By Scale of Operation, 2023-2033 (%)
Figure 10 Preclinical Scale of Operation in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 11 Clinical (Phase I, II, III) Scale of Operation in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 12 Commercial Manufacturing Scale of Operation in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 13 India Contract Development and Manufacturing (CDMO) Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 14 Pharmaceutical Companies End-User in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 15 Biotechnology Companies End-User in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 16 Contract Research Organizations End-User in India Contract Development and Manufacturing (CDMO) Market Value, 2022-2033 (US$ Billion)
Figure 17 Aurobindo Pharma Limited: Financials
Figure 18 Dr. Reddy’s Laboratories Ltd.: Financials
Figure 19 Sun Pharmaceutical Industries Ltd.: Financials
Figure 20 Lupin Limited: Financials
Figure 21 Cipla: Financials
Figure 22 NATCO Pharma Limited: Financials
Figure 23 Hetero Labs Limited: Financials
Figure 24 Cadila Pharmaceuticals: Financials
Figure 25 Biocon: Financials
Figure 26 Intas Pharmaceuticals Ltd.: Financials
